UCB (OTCMKTS:UCBJF) Shares Gap Up - What's Next?

Key Points

• UCB SA's share price increased from $241.83 to $251.19, indicating a positive market opening and interest in the stock.
• Morgan Stanley has reiterated an "overweight" rating on UCB's shares, with an overall average rating of "Buy" from analysts.
• The company boasts a debt-to-equity ratio of 0.33 and has been focused on developing products for neurology and immunology diseases.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $241.83, but opened at $251.19. UCB shares last traded at $251.19, with a volume of 32 shares.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an "overweight" rating on shares of UCB in a report on Monday, September 8th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy".

UCB Price Performance

The firm's 50-day moving average is $225.65 and its 200-day moving average is $194.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.